Comparison of the variability of the annual rates of change in FEV 1 determined from serial measurements of the pre- versus post-bronchodilator FEV 1 over 5 years in mild to moderate COPD: Results of the lung health study
dc.contributor.author | Tashkin, DP | |
dc.contributor.author | Wang, HJ | |
dc.contributor.author | Halpin, D | |
dc.contributor.author | Kleerup, EC | |
dc.contributor.author | Connett, J | |
dc.contributor.author | Li, N | |
dc.contributor.author | Elashoff, R | |
dc.date.accessioned | 2021-07-22T07:48:54Z | |
dc.date.issued | 2012-08-15 | |
dc.description.abstract | Background: The impact of interventions on the progressive course of COPD is currently assessed by the slope of the annual decline in FEV 1 determined from serial measurements of the post-, in preference to the pre-, bronchodilator FEV 1. We therefore compared the yearly slope and the variability of the slope of the pre- versus the post-bronchodilator FEV 1 in men and women with mild to moderate COPD who participated in the 5-year Lung Health Study (LHS).Methods: Data were analyzed from 4484 of the 5887 LHS participants who had measurements of pre- and post-bronchodilator FEV 1 at baseline (screening visit 2) and all five annual visits. The annual rate of decline in FEV 1 (±SE) measured pre- and post-bronchodilator from the first to the fifth annual visit was estimated separately using a random coefficient model adjusted for relevant covariates. Analyses were performed separately within each of the three randomized intervention groups. In addition, individual rates of decline in pre- and post-bronchodilator FEV 1 were also determined for each participant. Furthermore, sample sizes were estimated for determining the significance of differences in slopes of decline between different interventions using pre- versus post-bronchodilator measurements.Results: Within each intervention group, mean adjusted and unadjusted slope estimates were slightly higher for the pre- than the post-bronchodilator FEV 1 (range of differences 2.6-5.2 ml/yr) and the standard errors around these estimates were only minimally higher for the pre- versus the post-bronchodilator FEV 1 (range 0.05-0.11 ml/yr). Conversely, the standard deviations of the mean FEV 1 determined at each annual visit were consistently slightly higher (range of differences 0.011 to 0.035 L) for the post- compared to the pre-bronchodilator FEV 1. Within each group, the proportion of individual participants with a statistically significant slope was similar (varying by only 1.4 to 2.7%) comparing the estimates from the pre- versus the post-bronchodilator FEV 1. However, sample size estimates were slightly higher when the pre- compared to the post-bronchodilator value was used to determine the significance of specified differences in slopes between interventions.Conclusion: Serial measurements of the pre-bronchodilator FEV 1 are generally sufficient for comparing the impact of different interventions on the annual rate of change in FEV 1. © 2012 Tashkin et al.; licensee BioMed Central Ltd. | en_GB |
dc.identifier.citation | Vol. 13, article 70 | en_GB |
dc.identifier.doi | 10.1186/1465-9921-13-70 | |
dc.identifier.uri | http://hdl.handle.net/10871/126500 | |
dc.language.iso | en | en_GB |
dc.publisher | BMC | en_GB |
dc.rights | © 2012 Tashkin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | en_GB |
dc.subject | FEV1 decline | en_GB |
dc.subject | Chronic obstructive pulmonary disease (COPD) | en_GB |
dc.subject | Lung health study | en_GB |
dc.subject | Pre-bronchodilator | en_GB |
dc.subject | Post-bronchodilator | en_GB |
dc.title | Comparison of the variability of the annual rates of change in FEV 1 determined from serial measurements of the pre- versus post-bronchodilator FEV 1 over 5 years in mild to moderate COPD: Results of the lung health study | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-07-22T07:48:54Z | |
dc.identifier.issn | 1465-9921 | |
dc.description | This is the final published version, available from BMC via the DOI in this record. | en_GB |
dc.identifier.journal | Respiratory Research | en_GB |
dc.rights.uri | http://creativecommons.org/licenses/by/2.0 | en_GB |
pubs.euro-pubmed-id | MED:22894725 | |
dcterms.dateAccepted | 2012 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2012-08-15 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-07-22T07:44:03Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2021-07-22T07:49:26Z | |
refterms.panel | Unspecified | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2012 Tashkin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.